Trifluoperazine
Based on 10 publication(s) in Google Scholar
Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.87%
- CAS No.: 117-89-5
- Formule: C21H24F3N3S
- Masse moléculaire:407.50
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Trifluoperazine
More- J Transl Med. 2024 Aug 1;22(1):715. [Abstract]
- Free Radic Biol Med. 2025 Feb 1:227:64-79. [Abstract]
- CNS Neurosci Ther. 2023 Mar;29(3):831-841. [Abstract]
- Food Biosci. 2024 Feb, 57, 103513.
- Chem Biol Interact. 2024 Apr 1:392:110904. [Abstract]
- Mol Med Rep. 2021 May;23(5):319. [Abstract]
- Sci Rep. 2025 May 8;15(1):16053. [Abstract]
- BMC Med Genomics. 2024 Jan 2;17(1):12. [Abstract]
- Tohoku J Exp Med. 2022 Jul 22;257(4):315-326. [Abstract]
- bioRxiv. 2024 June 12.
Voir tous les produits spécifiques à Isoform Dopamine Receptor
MoreVoir tous les produits spécifiques à Isoform Adrenergic Receptor
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KG-1a | IC50 |
4.58 μM
Compound: TFP
|
Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay
Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay
|
[PMID: 31541872] |
| MCF7 | IC50 |
11.33 μM
Compound: TFP
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
|
[PMID: 31541872] |
| MDA-MB-231 | IC50 |
21.58 μM
Compound: TFP
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
|
[PMID: 31541872] |
| NCI-H1650 | GI50 |
12.2 μM
Compound: Trifluoperazine
|
Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26372073] |
| Neutrophil | IC50 |
12.2 μM
Compound: TFP
|
Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge
Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of beta-glucuronidase release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge
|
[PMID: 12662101] |
| Neutrophil | IC50 |
13.2 μM
Compound: TFP
|
Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge
Antiinflammatory activity in fMLP/cytochalasin B stimulated rat neutrophils assessed as inhibition of lysozyme release preincubated for 10 mins measured 45 mins after fMLP/cytochalasin B challenge
|
[PMID: 12662101] |
| Neutrophil | IC50 |
2.7 μM
Compound: TFP
|
Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil
Inhibition of PMA-induced superoxide formation in Sprague-Dawley rat neutrophil
|
[PMID: 16510283] |
| Neutrophil | IC50 |
6.6 μM
Compound: TFP
|
Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil
Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil
|
[PMID: 16510283] |
| Neutrophil | IC50 |
12.7 μM
Compound: TFP
|
Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils
Inhibition of 5 ug/ml CB-stimulated Lysozyme release from rat neutrophils
|
[PMID: 17320246] |
| Neutrophil | IC50 |
13.2 μM
Compound: TFP
|
Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils
Inhibition of 1 uM fMLP-stimulated beta-Glucuronidase release from rat neutrophils
|
[PMID: 17320246] |
| Neutrophil | IC50 |
11.9 μM
Compound: Trifluoperazine
|
Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release
Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced lysozyme release
|
[PMID: 19699097] |
| Neutrophil | IC50 |
12.5 μM
Compound: Trifluoperazine
|
Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release
Antiinflammatory activity against Sprague-Dawley rat neutrophils assessed as inhibition of fMLP/cytochalasin B-induced beta-glucuronidase release
|
[PMID: 19699097] |
| NIH-3T3-G185 | IC50 |
10.9 μM
Compound: Trifluoperazine
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
6.3 μM
Compound: Trifluoperazine
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
7.2 μM
Compound: Trifluoperazine
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NSC | IC50 |
10.1 μM
Compound: TFP
|
Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human NSC cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29614416] |
| Sf9 | IC50 |
0.0005 M
Compound: Trifluoperazine
|
Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
|
[PMID: 9873605] |
| Sf9 | IC50 |
0.5 mM
Compound: Trifluoperazine
|
Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
Inhibition of protein kinase C(1:1mixture of PKC alpha & beta) expressed in Sf9 insect cells
|
[PMID: 9873605] |
| SK-BR-3 | IC50 |
15.89 μM
Compound: TFP
|
Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
|
[PMID: 31541872] |
| SUM-159-PT | IC50 |
17.03 μM
Compound: TFP
|
Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay
|
[PMID: 31541872] |
| U-87MG ATCC | EC50 |
13.5 μM
Compound: TFP
|
Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay
Induction of intracellular Ca2+ level in human U87MG cells by Fura-2 AM dye-based assay
|
[PMID: 29614416] |
| U-87MG ATCC | IC50 |
9.9 μM
Compound: TFP
|
Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 29614416] |
Trifluoperazine is a long-established, widely used 'conventional' antipsychotic agent. Trifluoperazine has been an extensively studied drug molecule that has been used as a calmodulin inhibitor[3][4].
Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis, but not budding, by disturbing cellular CaM and/or CaM-dependent functions[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 117-89-5
-
Appearance Solid
-
Masse moléculaire 407.50
-
Formule C21H24F3N3S
-
Color Off-white to light yellow
-
SMILES
FC(C(C=C1N2CCCN3CCN(C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
J Transl Med
Suppression of NUPR1 in fibroblast-like synoviocytes reduces synovial fibrosis via the Smad3 pathway. [Abstract]2024 Aug 1;22(1):715. PMID: 39090667 -
Free Radic Biol Med
Zinc ions facilitate metabolic bioenergetic recovery post spinal cord injury by activating microglial mitophagy through the STAT3-FOXO3a-SOD2 pathway. [Abstract]2025 Feb 1:227:64-79. PMID: 39613048 -
CNS Neurosci Ther
Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling. [Abstract]2023 Mar;29(3):831-841. PMID: 36627756 -
-
Chem Biol Interact
Trifluoperazine activates AMPK / mTOR / ULK1 signaling pathway to induce mitophagy in osteosarcoma cells. [Abstract]2024 Apr 1:392:110904. PMID: 38360085 -
Mol Med Rep
Serum from patients with hypertension promotes endothelial dysfunction to induce trophoblast invasion through the miR‑27b‑3p/ATPase plasma membrane Ca2+ transporting 1 axis. [Abstract]2021 May;23(5):319. PMID: 33760199 -
Sci Rep
Estrogen regulates duodenal calcium absorption and improves postmenopausal osteoporosis by the effect of ERβ on PMCA1b. [Abstract]2025 May 8;15(1):16053. PMID: 40341576 -
BMC Med Genomics
Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma. [Abstract]2024 Jan 2;17(1):12. PMID: 38167084 -
Tohoku J Exp Med
Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1. [Abstract]2022 Jul 22;257(4):315-326. PMID: 35644544 -
Solvant et solubilité
DMSO : 125 mg/mL (306.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23(1):67-70. [Content Brief]
[2]. Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28. [Content Brief]
[3]. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545. [Content Brief]
[4]. Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54(1):20-22. [Content Brief]
[5]. Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15(2):149-160. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4540 mL | 12.2699 mL | 24.5399 mL | 61.3497 mL |
| 5 mM | 0.4908 mL | 2.4540 mL | 4.9080 mL | 12.2699 mL | |
| 10 mM | 0.2454 mL | 1.2270 mL | 2.4540 mL | 6.1350 mL | |
| 15 mM | 0.1636 mL | 0.8180 mL | 1.6360 mL | 4.0900 mL | |
| 20 mM | 0.1227 mL | 0.6135 mL | 1.2270 mL | 3.0675 mL | |
| 25 mM | 0.0982 mL | 0.4908 mL | 0.9816 mL | 2.4540 mL | |
| 30 mM | 0.0818 mL | 0.4090 mL | 0.8180 mL | 2.0450 mL | |
| 40 mM | 0.0613 mL | 0.3067 mL | 0.6135 mL | 1.5337 mL | |
| 50 mM | 0.0491 mL | 0.2454 mL | 0.4908 mL | 1.2270 mL | |
| 60 mM | 0.0409 mL | 0.2045 mL | 0.4090 mL | 1.0225 mL | |
| 80 mM | 0.0307 mL | 0.1534 mL | 0.3067 mL | 0.7669 mL | |
| 100 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6135 mL |
Trifluoperazine Related Classifications
HY-B0532 Related Classifications
Powered by Bioz